Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT05727722

PHASE1

Micro-encapsulated Hepatocyte Intraperitoneal Transplantation in Liver Failure Adults

Sponsor: RenJi Hospital

View on ClinicalTrials.gov

Summary

This is a prospective single-center dose escalation study of the administration of the microencapsulated hepatocyte therapy in adult liver failure. The purpose of the study is to determine the maximum tolerated dose of microencapsulated hepatocytes in liver failure patients and its effectiveness in treating the disease. We previously generated proliferating human hepatocytes (ProliHH) through dedifferentiation of PHH and engineered them into encapsulated liver organoids (eLO), providing an unlimited cell source for hepatocyte transplantation.

Official title: A Phase I Safety and Tolerability Dose Escalation Study of Micro-encapsulated Hepatocytes Intraperitoneal Transplantation Therapy for Adult Liver Failure Patients.

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

Start Date

2024-03-01

Completion Date

2026-02-28

Last Updated

2025-06-27

Healthy Volunteers

Conditions

Acute-On-Chronic Liver Failure Chronic Liver Failure

Interventions

BIOLOGICAL

a single course of micro-encapsulated hepatocytes intraperitoneal transplantation therapy

A single course will be divided into an "accelerated titration design" phase and a "3+3 design" phase to reduce the number of subjects exposed to potentially ineffective doses that may not benefit from treatment. The "accelerated titration design" phase starts at a starting dose of 0.15x10\^9, moving to the "3+3 design" phase at the dose of 0.5x10\^9. According to the semi-logarithmic incremental (10\^0.5-fold) approach, the treatment dosage was set into four groups at a maximum dose of 4.5×10\^9 (allowing for a ±20% difference between the actual dose and the planned dose, considering production specifics). The number or the incremental ratio of subsequent dose groups can be adjusted based on the evaluation of available data in the study, and intermediate doses can be explored.

Inclusion Criteria: A. Chronic liver failure (CLF) group: The progressive liver function decline or decompensation after liver cirrhosis: 1. Body weight\>40kg; 2. Aged between 18 to 65 years old; 3. Serum Total bilirubin was higher than the normal range and lower than 10 times the upper limit of normal value (ULN); 4. With or without significantly decreased serum albumin value, lower than 35; 5. With or without significantly decreased platelet (PLT) value, prothrombin activity (PTA)≤40% (or international normalized ratio (INR)≥1.5), other reasons excluded; 6. With or without refractory ascites or portal hypertension; 7. With or without a stage I or II hepatic encephalopathy; 8. No obvious improvement after more than 3 days' regular clinical treatments. OR B. Acute-on-chronic liver failure (ACLF) group: With known or unknown basic liver diseases, subjects undergoing acute liver failure syndrome (clinical manifestations indicated as an early stage liver failure). 1. Body weight\>40kg; 2. Aged between 18 to 65 years old; 3. With obvious fatigue, accompanied by other gastrointestinal symptoms such as anorexia, vomiting, and abdominal distension; 4. Complicated with ascites and/or hepatic encephalopathy within 4 weeks after being diagnosed; 5. Progressive aggravation of jaundice, total serum bilirubin≥85umol/L； 6. Coagulation disorders, INR\>1.5 or PTA\<40%; 7. No obvious improvement after more than 3 days' regular clinical treatments. Exclusion Criteria: 1. With obvious brain edema, cerebral hernia, or indicated intracranial hemorrhage; 2. Diagnosed or suspected as primary or metastatic liver cancer; 3. With uncorrectable oxygenation index (PaO2/FiO2)\<200; 4. With disseminated intravascular coagulation; 5. Active hemorrhage; 6. Uncontrollable infection, including ascites infection such as spontaneous bacterial peritonitis; 7. Uncorrectable decrease in PLT (\<20×109/L); 8. HIV and/or SARS-CoV-Ⅱ positive; 9. Drug abuse within 1 year; 10. Systemic hemodynamic instability; 11. Combined with pregnancy or lactation; 12. Other situations excluded by clinician;

Locations (1)

Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, China